Literature DB >> 30705098

Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.

Yohann Repessé1,2,3, Catherine Costa4, Roberta Palla5, Elika Farrokhi Moshai6, Annie Borel-Derlon1,2,3, Roseline D'Oiron7, Chantal Rothschild8, Amal El-Beshlawy9, Mohsen Elalfy10, Vijay Ramanan11, Peyman Eshghi12, Johannes Oldenburg13, Anna Pavlova13, Frits R Rosendaal14, Flora Peyvandi5, Srinivas V Kaveri6, Sébastien Lacroix-Desmazes15.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30705098      PMCID： PMC6669172          DOI： 10.3324/haematol.2018.212001

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  16 in total

1.  Dissecting intensive treatment as risk factor for inhibitor development in haemophilia.

Authors:  C L Eckhardt; A S van Velzen; C J Fijnvandraat; J G van der Bom
Journal:  Haemophilia       Date:  2016-04-14       Impact factor: 4.287

2.  Polymorphisms and mutations in vWF and ADAMTS13 genes and their correlation with plasma levels of FVIII and vWF in patients with deep venous thrombosis.

Authors:  Luis Fernando Bittar; Erich Vinícius de Paula; Tayana B T Mello; Lúcia H Siqueira; Fernanda L A Orsi; Joyce M Annichino-Bizzacchi
Journal:  Clin Appl Thromb Hemost       Date:  2010-08-03       Impact factor: 2.389

3.  Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity.

Authors:  Lysiane Hilbert; Sylvie Jorieux; Valérie Proulle; Rémi Favier; Jenny Goudemand; Armelle Parquet; Dominique Meyer; Edith Fressinaud; Claudine Mazurier
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

Review 4.  The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.

Authors:  Samantha C Gouw; H Marÿke van den Berg
Journal:  Semin Thromb Hemost       Date:  2010-02-18       Impact factor: 4.180

5.  The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Authors:  Jan Astermark; Sharyne M Donfield; Edward D Gomperts; John Schwarz; Erika D Menius; Anna Pavlova; Johannes Oldenburg; Bailey Kessing; Donna M DiMichele; Amy D Shapiro; Cheryl A Winkler; Erik Berntorp
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

6.  Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter.

Authors:  Yohann Repessé; Ivan Peyron; Jordan D Dimitrov; Suryasarathi Dasgupta; Elika Farrokhi Moshai; Catherine Costa; Annie Borel-Derlon; Benoit Guillet; Roseline D'Oiron; Achille Aouba; Chantal Rothschild; Johannes Oldenburg; Anna Pavlova; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

7.  Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes.

Authors:  Q Y Wang; J Song; R A Gibbs; E Boerwinkle; J F Dong; F L Yu
Journal:  J Thromb Haemost       Date:  2013-02       Impact factor: 5.824

8.  The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII.

Authors:  A Leyte; M P Verbeet; T Brodniewicz-Proba; J A Van Mourik; K Mertens
Journal:  Biochem J       Date:  1989-02-01       Impact factor: 3.857

9.  A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.

Authors:  Shannon L Meeks; Courtney L Cox; John F Healey; Ernest T Parker; Bhavya S Doshi; Bagirath Gangadharan; Rachel T Barrow; Pete Lollar
Journal:  Blood       Date:  2012-07-31       Impact factor: 22.113

10.  Identification of two point mutations in the von Willebrand factor gene of three families with the 'Normandy' variant of von Willebrand disease.

Authors:  C Gaucher; B Mercier; S Jorieux; D Oufkir; C Mazurier
Journal:  Br J Haematol       Date:  1991-08       Impact factor: 6.998
View more
  1 in total

Review 1.  Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.

Authors:  David W Scott; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-01-17       Impact factor: 8.786
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.